Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VIVO Cannabis Inc. V.PDA


Primary Symbol: VVCIF

Healthcare Drug Manufacturers - Specialty & Generic
VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.


OTCQB:VVCIF - Post by User

VIVO Cannabis Inc. > Q3 2020 came out Nov.12th last year
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Comment by JreBudon Nov 05, 2021 1:33pm
190 Views
Post# 34093047

RE:RE:RE:Q3 2020 came out Nov.12th last year

RE:RE:RE:Q3 2020 came out Nov.12th last year
Net revenue for Q2 2021 was $6.4 million, representing a 16% increase quarter-over-quarter as compared to Q1 2021. Sales, general and administrative expenses were $4.3 million in Q2 2021, compared to $4.1 million in Q1 2021, an increase of 5% driven by legal expenses related to conducting the AGM. The Company's adjusted EBITDA(1) was ($3.0) million for the quarter, compared to ($2.4) million in Q1 2021, the difference primarily driven by inventory write-downs taken in the quarter. Cash and cash equivalents decreased from $16.9M in Q1 2021 to $15.7M in Q2 2021, driven by the Company's operating losses. (3mil loss) Considering more expenses would come with additional sales.. still within reach.. just need one big deal! Growth in Australia and Germany, Also note premium high THC strains have been biggest growth in the sector. And that's us
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities